


Evidence-Based Mental Health



Contents

May 2016 Vol 19 No 2

Perspective

- 33 mHealth in psychiatry: time for methodological change

Clinical reviews

- 35 Ketamine for treatment-resistant depression: recent developments and clinical applications

- 39 Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies

- 43 Computerised cognitive behaviour therapy for major depression: a reply to the REEACT trial

Evidence-based case conference

- 46 Diagnosing autism spectrum disorder (ASD) among adults

Statistics in practice

- 49 Economic evaluation of mental health interventions: an introduction to cost-utility analysis

Causes and risk factors

- 54 High-potency cannabis increases the risk of psychosis
- 55 Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders
- 56 Support for the link between adolescent mental health problems and subsequent perinatal depression: a 20-year prospective cohort study

Outcomes

- 57 Treatment of maternal perinatal depression in a low-income setting does not lead to improved outcomes for children
- 58 Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders

Miscellaneous

- 59 A negative randomised sham-controlled trial of ventral capsule/ventral striatum stimulation in treatment-resistant depression: an unsuccessful trial or treatment?

Pharmacological interventions

- 60 Alpha-7 nicotinic agonist improves cognition in schizophrenia
- 61 Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis
- 62 Unnecessary psychotropic drug prescription in primary care for people with intellectual disability

Psychological interventions


- 63 Psychodynamic therapy: a poorly defined concept with questionable evidence


Letter

- 64 Psychodynamic therapy: a well-defined concept with increasing evidence

Electronic pages

- e6 Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?
- e7 Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression
- e8 Long-acting injectable risperidone as an option in first-episode psychosis
- e9 Clonidine: new use of an old medication to reduce stress-related substance use

 This article has been chosen by the Editor to be of special interest or importance and is freely available online.

 This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ebmh.bmj.com/site/about/guidelines.xhtml#open>

 This journal is a member of and subscribes to the principles of the Committee on Publication Ethics www.publicationethics.org

 equator network

 recycle
When you have finished with this please recycle it

Receive regular table of contents by email.
Register using this QR code.

